History
Progressive supranuclear palsy (PSP) is a neurodegenerative disease that usually begins in a person's 60s or 70s; as parts of the brain gradually break down over time, problems develop with balance, eye movements, speech and swallowing, and thinking and behavior. The name may sound difficult, but "progressive" means that it worsens over time, and "supranuclear" conveys that the eye movement disorder arises not from the nerve nuclei that move the eyes themselves, but from damage to the higher circuits above them that control those nuclei. So although the eyes may look as if they are "broken," it can be understood that the symptoms actually arise because the brain's control system has broken down.
Historically, from the late 19th century, patients who resembled those with Parkinson's disease but had unusually early falls and prominent eye movement problems were rarely reported. In the 1950s, as the clinical course and autopsy findings of similar groups of patients accumulated, discussion grew that the condition was difficult to explain as Parkinson's disease alone. The decisive turning point came in 1963, when Richardson, Steele, and Olszewski grouped together the common clinical features seen in multiple patients (early falls, eye movement disorders, rigidity of the neck and trunk, speech and swallowing problems, etc.) and the characteristic pathological findings and presented them as a single independent disease. For this reason, the name Steele-Richardson-Olszewski syndrome is also used.
For a long time afterward, the "typical presentation" was emphasized, but as diagnostic criteria and observation techniques advanced, it became increasingly clear that there are subtypes with varied initial presentations. In recent research, there is a growing trend to view these varied initial presentations as a single spectrum and to distinguish subtypes at an earlier stage in order to predict prognosis and set management goals.
The philosophy of treatment has also changed. Since there is no "cure-all drug," the recognition has become established that, rather than trying to solve the problem with medication alone, multidisciplinary management is key, including rehabilitation to reduce complications such as falls and aspiration, safe eating strategies, communication aids, and family caregiving plans.
Causes
It is difficult to establish a single cause. In most cases there is no family history, and it does not present like a typical hereditary disease caused by one specific gene. Therefore, the most realistic explanation is that "several factors overlap to raise the risk." However, the most important clue for inferring the cause is the fact that a particular protein accumulates abnormally in the brain.
The key protein in PSP is tau. Tau normally stabilizes structures that serve as the "cytoskeleton" inside nerve cells, helping to prevent the collapse of the passages along which substances move within the cell. However, when tau changes into an abnormal form and is not broken down well, it accumulates like clumps, preventing nerve cells from working properly and ultimately causing the cells to die. PSP is characterized in particular by excessive accumulation of a form of tau called 4-repeat tau (4R tau), and the disease is therefore sometimes classified as a type of "tauopathy."
So the core of the discussion of causes is "why tau accumulates in this way," but there is still no single answer. The risk increases with age, genetic vulnerability can raise the risk, and the possibility that environmental factors or metabolic and vascular health have an influence is being discussed. In actual practice, the most important message is "managing the symptoms and risks that have appeared to reduce complications" rather than "finding the cause."
In particular, because falls and swallowing disorders greatly affect the prognosis regardless of the cause, early intervention has great value.
Genetic Epidemiology
PSP occurs sporadically in most cases, but the genetic background that raises the risk of developing it is relatively well known. Typically, a particular genotype (haplotype) around the microtubule-associated protein tau (MAPT) gene is reported to be associated with PSP. In particular, the H1 haplotype is observed more commonly in patient groups and is understood as "a constitution that raises the risk." Because this genotype can affect the way tau is produced and regulated, it is drawing attention as a candidate linked to the core pathology of PSP (tau accumulation).
A very important point is the fact that having this genotype does not mean that PSP will necessarily develop. The H1 haplotype is common in the general population as well, and most people never experience PSP. In other words, the genetic factor is closer to a "vulnerability" that raises the risk when aging or other biological conditions are also present, rather than a "necessary condition." This explanation is important in helping family members not to worry excessively that "because it is hereditary, the family will surely get it too."
Recent research understands the genetics of PSP not as being explained by a single mutation, but as a multifactorial structure in which several genetic variants each change the risk slightly. The possibility that the genetic background and the distribution of pathology differ according to clinical subtype (the typical form, the parkinsonian form, forms with prominent language and behavioral changes, etc.) is also being discussed. For general readers, it is sufficient to understand it roughly as "it mostly occurs without a family history, but a particular genetic background may raise the risk slightly."
General Epidemiology
PSP is classified as a rare disease. Figures vary between studies, but the overall prevalence is generally reported to be at the level of a few people per 100,000 population. Onset usually begins in a person's 60s or 70s and is rare at earlier ages. Sex differences are either small or reported slightly differently from study to study, and clinically, the point that "the risk increases with age" is more important.
The reason diagnosis is delayed is that the early symptoms overlap with those of various parkinsonian disorders, including Parkinson's disease. In the beginning, it can start with common descriptions such as "walking has become slower," "the body feels stiff," or "speech has become slurred," and in some cases the eye movement disorder is not evident early on. Over time, as backward falls recur and features such as difficulty looking downward become clear, the likelihood of PSP increases.
Recent research concludes that as diagnostic criteria have become more refined and awareness among medical staff has increased, not only the typical form (Richardson type) but also various subtypes, such as the parkinsonian type, the progressive gait freezing type, the frontal type, and the speech/language type, are being diagnosed more actively. Another epidemiologically important fact is that the course varies greatly under the diagnosis of PSP. Therefore, for actual practice and care planning, it is more important to look not only at prevalence but also at which complication risks (falls, swallowing, cognitive and behavioral changes) are high for each subtype and what caregiving resources are needed.
Pathogenesis
The pathogenesis can be explained as "a process in which specific circuits of the brain gradually break down as tau protein accumulates abnormally." Tau stabilizes the microtubules inside nerve cells, maintaining the "rails" along which substances move within the cell. In PSP, 4-repeat tau (4R tau) in particular increases excessively and, because it is not broken down well, forms clumps (deposits), which destroy the structure and function of nerve cells.
This change is not a problem of nerve cells alone. The brain has supporting cells that assist nerve cells (astrocytes, oligodendrocytes, etc.), and in PSP, tau can also accumulate abnormally in these supporting cells. Supporting cells create a favorable environment for nerve cells to live in and respond to damage; when supporting cell function also declines, the brain's microenvironment worsens, and inflammatory responses and oxidative stress may persist.
The vulnerable areas in PSP are the midbrain and brainstem, the basal ganglia, and the circuits connected to the frontal lobe. The midbrain and brainstem circuits are important for up-and-down eye movements and for balance and postural reflexes. This is why the characteristic features of difficulty looking downward, falling backward, and a stiff posture appear. Damage to the basal ganglia circuits produces slow movements and rigidity, and damage to the frontal lobe circuits can produce cognitive and behavioral changes such as apathy, reduced planning and organizing abilities, and problems with impulse control.
Recent research seeks to track what changes begin "before symptoms become clinically evident" in PSP. Attempts are described that combine subtle slowing of eye movements, markers of nerve damage measurable in blood and cerebrospinal fluid, and atrophy or reduced function of specific areas observed on imaging to capture early changes. The purpose of such approaches lies not only in early diagnosis but also in establishing objective measures to evaluate whether treatments developed in the future slow the progression of the disease.
Symptoms
Symptoms usually begin as inconveniences in daily life. The most typical starting point is unsteady balance and falling. In PSP, backward falls can recur relatively early, which increases the risk of fractures and head injuries. Walking becomes slower and the body becomes stiff, and a feeling that the trunk and neck are stiffer than the arms and legs (axial rigidity) may appear.
Problems with vision and eye movement are central to understanding PSP. Rather than vision itself deteriorating, the action of quickly moving the eyes up and down to find a target becomes difficult. As a result, it is hard to look down when going down stairs, and the risk of falling increases because the boundary between the toes and the floor cannot be seen well. It is also common to lose one's place in a line when reading a book or to move the head excessively when looking at a mobile phone screen. Blinking decreases, so the eyes easily become dry, and some people complain that their eyelids do not open easily or feel as though they close involuntarily.
Changes in speech and swallowing are also common. Pronunciation becomes slurred and speech slows, and the voice may become quiet or weak. When swallowing becomes sluggish, people choke when drinking water, feel as if food is stuck in the throat, and take longer to eat. As it progresses, weight loss and malnutrition may occur, and the risk of aspiration pneumonia, caused by food entering the airway, increases.
The degree of cognitive and behavioral change differs from person to person, but apathy (loss of motivation), reduced concentration, and reduced planning and organizing abilities may appear. Family members may perceive this as "they have become depressed" or "their personality has changed," so a process of explaining it as distinct from depression is needed. Because the starting point of PSP symptoms differs according to subtype, identifying early whether the "falls and eye movement axis," the "parkinsonism axis," or the "language and behavior axis" comes first helps in diagnosis and in estimating prognosis.
Signs
Signs are objective findings that medical staff confirm on examination. The representative sign of PSP is a vertical eye movement disorder. In particular, it can appear as difficulty shifting the gaze downward or as slowing of the saccades, the quick "flicking" movements of the eyes used to find a target. Patients say things like "stairs are frightening" or "I can't follow the letters well," but they often do not accurately recognize the eye movement problem themselves. On examination, there are cases in which the eyes reflexively follow to some extent when the head is moved, so the characteristic that "it does not work well voluntarily, but works a little reflexively" serves as a clue.
Impaired postural reflexes and the gait pattern are also important signs. Even when balance is lightly disturbed, the person may be unable to recover their center and may stagger backward considerably, and the risk of falling when changing direction is high. Rigidity of the neck and trunk is prominent, and a posture with the neck tilted backward may appear. Because tremor may not be as common as in Parkinson's disease, the combination of "no tremor, but slow and stiff movements and frequent falls" helps the diagnosis.
Signs related to speech and swallowing include dysarthria (imprecise pronunciation), reduced vocal output, coughing when swallowing, and a sensation of residual food. Recent research concludes that observing eye movement assessments more precisely (speed, range, pattern) can help in suspecting PSP even at a stage when gaze palsy is not yet clinically evident. Therefore, when PSP is suspected, it is important to look at both the speed and responsiveness of eye movements.
Screening
There is no "single screening test" that identifies PSP at once. Therefore, actual screening is carried out by catching "warning signs" through the medical history and a simple examination and, if necessary, referring the person to specialist care. The key to screening is to check four axes in a short time.
First, falls. Ask whether there have been repeated falls relatively early after the onset of symptoms, especially whether there has been a pattern of falling backward. Second, vision and eye movement. Check whether it is difficult to look down or go down stairs, and whether the person loses their place in a line when reading a book. Third, speech and swallowing. Ask whether speech has become slurred, whether choking on water or food has become frequent, and whether mealtimes have become longer. Fourth, behavior and cognition. Check whether apathy, problems with impulse control, reduced concentration, or slowing of task performance accompany these.
On examination, eye movement testing (shifting the gaze up and down, quickly following a target) and observation of posture and gait are basic. However, because there is a risk of falling during postural reflex assessment, safety must always be ensured. Since the purpose of screening is not confirmation but "noticing the risk quickly and beginning safety measures," it is necessary to make plans for fall prevention and swallowing risk assessment from the moment it is suspected.
Recent research describes attempts to distinguish PSP from other parkinsonian disorders from a very early stage by quantifying eye movements with equipment or by combining blood and cerebrospinal fluid markers with imaging markers. However, for screening in general practice, the most realistic approach is still not to miss the combination of "fall pattern + eye movement clues + speech and swallowing problems."
Diagnosis
Diagnosis is based on "the combination of clinical features" and proceeds by supporting this with imaging and functional assessments. First, after PSP is suspected from the medical history and neurological examination, it is differentiated from other atypical parkinsonian disorders such as Parkinson's disease, multiple system atrophy (MSA), and corticobasal degeneration (CBD). The facts that tremor may not be prominent in PSP, that the response to levodopa is weak or temporary, and that falls and eye movement disorders can appear relatively early help in the differentiation.
For imaging, brain magnetic resonance imaging (MRI) is most commonly used. The midbrain is atrophied while the pons is relatively preserved, which can look like a particular shape (the so-called "hummingbird" sign), and such findings support the clinical diagnosis. More quantitatively, indices calculated by measuring specific areas, such as the Magnetic Resonance Parkinsonism Index (MRPI), may be used.
Because swallowing symptoms are important, if necessary, the risk of aspiration is checked with a videofluoroscopic swallowing study (VFSS) or fiberoptic endoscopic evaluation of swallowing (FEES). Ophthalmologic evaluation helps assess double vision, eyelid problems, and eye movements. In some cases, functional imaging such as fluorodeoxyglucose positron emission tomography (FDG-PET) may be considered as an adjunct.
Recent research emphasizes that, in order to distinguish the various subtypes and PSP-like diseases, "the key to diagnosis is how accurately the combination of clinical features is interpreted rather than a single test." Ultimately, the goal of diagnosis is not only to attach a label, but to help manage the risks of falls and swallowing early and to begin rehabilitation and care plans quickly.
Treatment
At present, no definitive treatment has been established that fundamentally stops PSP. Therefore, the purpose of treatment is to reduce symptoms, prevent complications such as falls and aspiration, and help maintain daily function for as long as possible. Treatment often focuses on "daily functioning and safety" rather than on medication.
Drug treatment is limited but can be meaningful. Levodopa tends to have a weak effect in PSP, but because some subtypes may feel a benefit for a while in the early stage, it can be tried. Amantadine sometimes helps with lethargy or slowness of movement, and botulinum toxin injections are sometimes considered for dystonia or eyelid spasm. Depression and anxiety, sleep problems, bladder symptoms, constipation, and so on are each managed carefully with appropriate drugs.
The core of treatment is rehabilitation and environmental adjustment. Physical therapy focuses on learning gait and balance training and fall prevention strategies and on maintaining muscle strength and flexibility. Occupational therapy adjusts the home environment and tools so that daily activities such as dressing, eating, moving around, and bathing can be done more safely. Speech therapy provides not only voice and articulation training but also swallowing rehabilitation and education on eating methods (posture, bite size, adjusting consistency).
Management of nutrition and respiratory complications is also part of treatment. If mealtimes become excessively long or weight decreases, nutritional counseling is needed, and if there is a recurring risk of aspiration, dietary adjustment and swallowing rehabilitation are applied more actively. Environmental adjustments to reduce falls, such as removing thresholds in the home, installing grab bars, and improving nighttime lighting, are "treatment" as important as medication. At present, "symptomatic treatment + rehabilitation + prevention of complications + care planning" is the standard approach.
Prognosis
The prognosis varies between individuals but is generally progressive. In the typical form, walking becomes unsteady and falls become frequent relatively early, and over time a walking aid or wheelchair may become necessary. When eye movement disorders and postural instability overlap, the risk of falls and fractures increases, and a vicious cycle can arise in which fear of falling reduces activity and muscle strength declines further.
As speech and swallowing problems progress, weight loss and nutritional problems develop, and the risk of aspiration, in which food enters the airway, increases. Aspiration pneumonia is an important complication, and if it recurs, overall physical strength can decline rapidly. Therefore, a realistic strategy for changing the prognosis often depends on "how well complications are prevented, how well nutrition and activity are maintained, and how quickly a caregiving system is put in place, in a situation where there is no drug that stops the disease."
The course may differ depending on the subtype. Some cases show a relatively gradual course, as in the parkinsonian type, while in others, as in the typical form, falls and eye movement problems worsen rapidly. In addition, the prognosis should be understood as including not only survival time but also quality of life. When communication aids, safe mobility, and connection to appropriate caregiving resources are in place, the burden that patients and families feel in "daily life" can change greatly.
Therefore, it is necessary for prognostic assessment to be discussed realistically, including not only the medical course but also the family's caregiving capacity, the living environment, and access to rehabilitation.
Prevention
At present, no method of reliably preventing PSP is known. This is because the cause of onset is not singular, and aging, genetic vulnerability, and various environmental and biological factors are presumed to act in combination. Therefore, the realistic goals are lifestyle management to protect overall brain health and secondary prevention after onset (prevention of complications), rather than primary prevention (preventing the onset itself).
In terms of overall health management, approaches that protect cerebrovascular and metabolic health are recommended, such as managing blood pressure, blood sugar, and lipids, quitting smoking, exercising regularly, and managing sleep and nutrition. Although it cannot be asserted that these prevent PSP, they can help maintain the health of the nervous system throughout old age and lower the risk of falls.
The core of prevention after diagnosis is fall prevention and aspiration prevention. To prevent falls, the home environment is improved (removing thresholds, nonslip measures, grab bars, improved lighting), an appropriate walking aid is chosen in consideration of the risk of falling backward, and strategies for changing direction and using stairs are practiced. To prevent aspiration, a swallowing evaluation is performed early, and specific strategies such as adjusting consistency, eating posture, bite size, and pace are applied.
In the long term, care planning is part of prevention. Planning in advance who will respond and how when acute problems such as a fall or aspiration occur, how nighttime care and mobility assistance will be handled, and how to connect with rehabilitation and community resources helps reduce complications. Recent research emphasizes that multidisciplinary management centered on specialized centers is key to reducing complications and maintaining quality of life.